# EA3191: HCP commentary report

> 9 HCP sources screened · 116 verified claims from 9 sources · 8 findings. Updated 2026-10-07.

## Report

- Trial: A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
- NCT ID: NCT04671667
- Registry: https://clinicaltrials.gov/study/NCT04671667
- Sponsor: National Cancer Institute (NCI)
- Phase: Phase 2
- Status: Recruiting
- Drugs: carboplatin, cisplatin, pembrolizumab
- Indications: Head and neck squamous cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-07
- Last checked: 2026-10-07
- Release hash: b2013786f75a6b2db43ddfd6228ddc5fad068187a3c2fa93903adaecf4e863ef

## Counts

- HCP commentary sources screened: 9
- Sources cited by verified claims: 9
- Verified claims: 116
- Findings: 8
- People found in screened sources: 29
- People identity-verified: 24
- Voices cited: 13

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

EA3191 frames a clinician question: can pembrolizumab replace chemotherapy with another radiation course after surgery for previously irradiated, high-risk recurrent or second-primary head and neck squamous cell cancer? Clinician discussions also cover the comparator’s role, resectability, preoperative immunotherapy, treatment sequencing, symptoms and systemic-treatment alternatives. Other topics include cumulative-dose estimation, organ recovery, nerve injury risk, treatment goals, supportive care, referral, consent and trial access. The account draws on supplied video, podcast and X-thread commentary.

## Open Medical Affairs question

How should Medical Affairs explain the rationale for replacing postoperative platinum chemoradiation without implying that pembrolizumab has already improved efficacy or reduced toxicity?

## Findings (titles)

- F1. A potentially less-toxic replacement is the hope—not an established advantage
- F2. Resectability and patient goals separate the curative discussion from systemic treatment and response-dependent deferral
- F3. Symptom burden makes control-arm composition consequential in the connected discussion of alternative trials
- F4. Brachial plexus protection is described as a cumulative-dose, interval and counseling problem
- F5. Reirradiation questions extend from diagnosis and intent to dose, field size and acceptable harm
- F6. Cumulative-dose calculations and recovery assumptions are viewed as uncertain and operationally fragile
- F7. Multidisciplinary support is part of treatment feasibility, including during palliative systemic therapy
- F8. Access, consent and accrual are practical conditions for answering the research question

## Sample findings

### F4. Brachial plexus protection is described as a cumulative-dose, interval and counseling problem

A speaker in an X thread asked how to reduce brachial plexus injury during repeat radiation when treatment fields overlap.

Source: X thread, 2025-08-16.

### F6. Cumulative-dose calculations and recovery assumptions are viewed as uncertain and operationally fragile

Speakers in an X thread asked whether recovery estimates should address organs other than the spinal cord and whether quality assurance should be part of reirradiation.

Source: X thread.

## Trial aspects

| Aspect | Coverage | Claims | Sources |
| --- | --- | ---: | ---: |
| Postoperative replacement rationale and comparator status | discussed | 13 | 4 |
| Resectability, prognosis and preoperative immunotherapy | discussed | 20 | 2 |
| Response-dependent sequencing and temporary deferral | discussed | 6 | 2 |
| Symptoms and alternative systemic-trial choices | discussed | 12 | 2 |
| Brachial plexus dose estimation, interval and neurologic risk | discussed | 8 | 1 |
| Reirradiation definition, work-up, intent and technique | discussed | 14 | 1 |
| Recovery assumptions, cumulative-dose calculations and QA | discussed | 10 | 1 |
| Function, symptoms and multidisciplinary support | discussed | 6 | 1 |
| Postoperative selection, referral, consent and accrual | discussed | 14 | 5 |
| Observed comparative survival, symptom and safety outcomes | assessment incomplete | 0 | 0 |

## Cited sources by channel

- Podcasts: 1
- X threads: 5
- YouTube: 3

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice.

- Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- 8 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
- The reviewed discussion is not representative of all HCP views. Searches centered on identifiers and aliases may have missed unnamed references or different transcription variants.
- Related panel recordings and repeated organizational posts are not independent endorsements and should not be used to estimate consensus.
- The unidentified video respondent cannot be named from the supplied source. A named podcast passage does not establish ownership of the video remarks.
- Some connected discussion is not fully represented: treatment-selection rationale in the case recap, timing of multidisciplinary re-engagement, dose-recovery guidance and its qualifications, renal-function-dependent systemic alternatives, alternative-agent durability and HPV-related evidence limits, and biomarker-based selection among bispecifics. These omissions limit the completeness of the reported decision rationales.
- No exact-trial publication, comparative readout or full protocol document was available. Reported regimen, eligibility and dose-limit details remain attached to the speakers who described them.
- Post and publication dates are not confirmed session dates. Local availability, enrollment and renovation accounts describe their presentation setting, not assured current access.
- Broader reirradiation opinions include other treatment intents and disease sites; they do not establish EA3191-specific dose, target-volume or technique recommendations.
- Some presenters have limited separate professional context. Their source-established identities do not justify assuming additional clinical credentials or giving their claims greater evidentiary weight.
- The patient-facing video's rendered clinicaltrials.gov link contains NCT05533558 rather than the target NCT04671667; it is retained as transcribed, not endorsed as a verified referral link.

## Offer

- Size: Focused (9 commentary sources cited)
- Current edition: $750. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (24 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ea3191-nct04671667
- Agents: POST https://www.erudio.com/api/orders with {"report": "ea3191-nct04671667", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=ea3191-04671667

## Cite

Erudio Health. EA3191 (NCT04671667): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-07. https://www.erudio.com/reports/ea3191-nct04671667

## Machine access

- JSON: https://www.erudio.com/reports/ea3191-nct04671667.json
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "ea3191-04671667"}`